Strategic focus Target opportunities in metabolic diseases and obesity where MetAP2 inhibitors are relevant, such as type 2 diabetes and Prader-Willi syndrome, aligning outreach with Zafgen’s core R&D thesis and current disease focus.

Clinical-stage leverage Position collaborations around clinical-stage assets and MetAP2 programs to co-develop or co-fund trials, leveraging Zafgen’s ongoing development efforts and interest from potential pharma partners seeking early-to-mid stage partnerships.

Financial capacity Highlight potential financing or strategic partnership angles given Zafgen’s well-capitalized status and recent leadership/financing activities to support scaled development and potential license deals.

Strategic partnerships Explore mergers, collaborations, or technology-sharing arrangements with larger biotech or pharma players to accelerate MetAP2 inhibitor programs or to integrate Zafgen’s systems biology insights into broader metabolic disease platforms.

Leadership and timing Engage with Zafgen on sponsor-driven development milestones, leveraging the recent appointment of a Chief Development Officer and leadership strengthening to align on strategic deal timelines and value inflection points.